Journal article

Synchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6.5 mammary tumors

Yuqing Yang, Agnieszka Swierczak, Mohammad Ibahim, Premila Paiva, Leonie Cann, Andrew W Stevenson, Jeffrey C Crosbie, Robin L Anderson, Peter AW Rogers



BACKGROUND: Synchrotron microbeam radiation therapy (MRT) is a new, evolving form of radiotherapy that has potential for clinical application. Several studies have shown in preclinical models that synchrotron MRT achieves equivalent tumor control to conventional radiotherapy (CRT) but with significantly reduced normal tissue damage. METHODS: To explore differences between these two modalities, we assessed the immune cell infiltrate into EMT6.5 mammary tumors after CRT and MRT. RESULTS: CRT induced marked increases in tumor-associated macrophages and neutrophils while there were no increases in these populations following MRT. In contrast, there were higher numbers of T cells in the MRT treat..

View full abstract


Funding Acknowledgements

This research was undertaken on the Imaging and Medical Beam Line (IMBL) at the Australian Synchrotron, Victoria, Australia. The authors wish to acknowledge the following funding: JCC and PP (NH& MRC Early Career Research Fellowships), RLA (National Breast Cancer Foundation of Australia) and MI support from The Malaysian Government. We acknowledge grant funding from Cancer Council Victoria. The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational Infrastructure Support Program.